Myocardial infarction in young patients without coronary atherosclerosis: Assume primary antiphospholipid syndrome until proved otherwise

International Journal of Clinical Practice

Volumn 61, Issue 3, 2007, Pages 379-384

  Davies, J O J ^a   Hunt, B J ^a,b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; WARFARIN;

ADULT; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; CORONARY ARTERY ATHEROSCLEROSIS; DIAGNOSTIC TEST; FEMALE; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGE OF ONSET; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; TREATMENT OUTCOME; WARFARIN;

EID: 33847073778     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01245.x     Document Type: Article

References (39)

1. Sletnes KE, Smith P, Abdelnoor M, Arnesen H, Wisloff F. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke. Lancet 1992; 339: 451-3.
2. Vaarala O, Manttari M, Manninen V et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995; 91: 23-7.
3. Hamsten A, Norberg R, Bjorkholm M, de Faire U, Holm G. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1986; 1: 113-6.
4. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
5. Robertson B, Greaves M. Antiphospholipid syndrome: an evolving story. Blood Rev 2006; 20: 201-12.
6. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-7.
7. Jalowiec DA, Hill JA. Myocardial infarction in the young and in women. Cardiovasc Clin 1989; 20: 197-206.
8. Osula S, Bell GM, Hornung RS. Acute myocardial infarction in young adults: causes and management. Postgrad Med J 2002; 78: 27-30.
9. Cervera R, Piette JC, Font J et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002; 46: 1019-27.
10. Alegria JR, Herrmann J, Holmes DR Jr, Lerman A, Rihal CS. Myocardial bridging. Eur Heart J 2005; 26: 1159-68.
11. Takeuchi S, Obayashi T, Toyama J. Primary antiphospholipid syndrome with acute myocardial infarction recanalised by PTCA. Heart 1998; 79: 96-8.
12. Ho YL, Chen MF, Wu CC, Chen WJ, Lee YT. Successful treatment of acute myocardial infarction by thrombolytic therapy in a patient with primary antiphospholipid antibody syndrome. Cardiology 1996; 87: 354-7.
13. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-11.
14. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185-90.
15. Vaarala O. Antiphospholipid antibodies and myocardial infarction. Lupus 1998; 7 (Suppl. 2): S132-4.
16. Bili A, Moss AJ, Francis CW, Zareba W, Watelet LF, Sanz I. Anticardiolipin antibodies and recurrent coronary events: a prospective study of 1150 patients. Thrombogenic Factors, and Recurrent Coronary Events Investigators. Circulation 2000; 102: 1258-63.
17. De Caterina R, d'Ascanio A, Mazzone A et al. Prevalence of anticardiolipin antibodies in coronary artery disease. Am J Cardiol 1990; 65: 922-3.
18. Phadke KV, Phillips RA, Clarke DT, Jones M, Naish P, Carson P. Anticardiolipin antibodies in ischaemic heart disease: marker or myth? Br Heart J 1993; 69: 391-4.
19. Vaarala O. Antiphospholipid antibodies and atherosclerosis. Lupus 1996; 5: 442-7.
20. Okamoto R, Saito K, Miyahara M et al. Acute myocardial infarction in a patient with anomalous left coronary artery origin and primary antiphospholipid syndrome. Jpn Circ J 2000; 64: 214-7.
21. Krishnamurthy M, Desai R, Patel H. Spontaneous coronary artery dissection in the postpartum period: association with antiphospholipid antibody. Heart 2004; 90: e53.
22. Morgan-Hughes G. Acute myocardial infarction in young adults. Postgrad Med J 2002; 78: 381.
23. Crowther MA, Ginsberg JS, Julian J et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-8.
24. Finazzi G, Marchioli R, Brancaccio V et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3: 848-53.
25. Khamashta MA, Hunt BJ. Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? No. J Thromb Haemost 2005; 3: 844-5.
26. Nesher G, Ilany J, Rosenmann D, Abraham AS. Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin Arthritis Rheum 1997; 27: 27-35.
27. Nihoyannopoulos P, Gomez PM, Joshi J, Loizou S, Walport MJ, Oakley CM. Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies. Circulation 1990; 82: 369-75.
28. Amital H, Langevitz P, Levy Y et al. Valvular deposition of antiphospholipid antibodies in the antiphospholipid syndrome: a clue to the origin of the disease. Clin Exp Rheumatol 1999; 17: 99-102.
29. Garcia-Torres R, Amigo MC, de la RA, Moron A, Reyes PA. Valvular heart disease in primary antiphospholipid syndrome (PAPS): clinical and morphological findings. Lupus 1996; 5: 56-61.
30. Khamashta MA, Cervera R, Asherson RA et al. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet 1990; 335: 1541-4.
31. D'Cruz DP. Renal manifestations of the antiphospholipid syndrome. Lupus 2005; 14: 45-8.
32. Brown JH, Doherty CC, Allen DC, Morton P. Fatal cardiac failure due to myocardial microthrombi in systemic lupus erythematosus. Br Med J (Clin Res Ed) 1988; 296: 1505.
33. Murphy JJ, Leach IH. Findings at necropsy in the heart of a patient with anticardiolipin syndrome. Br Heart J 1989; 62: 61-4.
34. Leung WH, Wong KL, Lau CP, Wong CK, Liu HW. Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med 1990; 89: 411-9.
35. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 2000; 9: 170-5.
36. Manzi S, Meilahn EN, Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408-15.
37. Jara LJ, Medina G, Vera-Lastra O, Shoenfeld Y. Atherosclerosis and antiphospholipid syndrome. Clin Rev Allergy Immunol 2003; 25: 79-88.
38. Williams MJ, Restieaux NJ, Low CJ. Myocardial infarction in young people with normal coronary arteries. Heart 1998; 79: 191-4.
39. Jolobe OM. Acute myocardial infarction in young adults. Postgrad Med J 2002; 78: 381.